Selective Estrogen Receptor Modulators in Gynecology Practice.
Journal
Clinical obstetrics and gynecology
ISSN: 1532-5520
Titre abrégé: Clin Obstet Gynecol
Pays: United States
ID NLM: 0070014
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
pubmed:
27
7
2021
medline:
24
11
2021
entrez:
26
7
2021
Statut:
ppublish
Résumé
Selective estrogen receptor (ER) modulators have variable tissue specific estrogen agonist and antagonist activities. Tamoxifen is approved for treatment and prevention of breast cancer; acts as an endometrial estrogen agonist. Raloxifene is approved for prevention and treatment of osteoporosis and prevention of breast cancer. The selective ER modulators bazedoxifene paired with conjugated estrogens relieves vasomotor symptoms and prevents bone loss with neutral effects on breast and amenorrhea similar to placebo. Ospemifene is approved to treat dyspareunia. Lasofoxifene is in development for resistant ER positive breast cancer. Estetrol (E4), synthesized by human fetal liver, has dual weak-estrogenic/antiestrogenic features, now approved as a contraceptive.
Identifiants
pubmed: 34310353
doi: 10.1097/GRF.0000000000000647
pii: 00003081-202112000-00009
doi:
Substances chimiques
Estrogens, Conjugated (USP)
0
Selective Estrogen Receptor Modulators
0
Raloxifene Hydrochloride
4F86W47BR6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
803-812Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Liu JH. Selective estrogen receptor modulators (SERMS): keys to understanding their function. Menopause. 2020;27:1171–1176.
Pinkerton JV, Conner EA. Beyond estrogen: advances in tissue selective estrogen complexes and selective estrogen receptor modulators. Climacteric. 2019;22:140–147.
The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24:728–753.
Pinkerton JV. Hormone therapy for postmenopausal women. N Engl J Med. 2020;382:446–455.
Pinkerton JV, Thomas S. Use of SERMs for treatment in postmenopausal women. J Steroid Biochem Mol Biol. 2014;142:142–154.
Harvey HA, Kimura M, Hajba A. Toremifene: an evaluation of its safety profile. Breast. 2006;15:142–157.
Vogel CL, Johnston MA, Capers C, et al. Toremifene for breast cancer: a review of 20 years of data. Clin Breast Cancer. 2014;14:1–9.
Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet. 2013;381:1827–1834.
Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila). 2010;3:696–706.
Davies C, Pan H, Godwin J, et al. Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial. Lancet. 2013;381:805–816.
Chlebowski RT, Pan K. Adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379:1684.
Tseng OL, Spinelli JJ, Gotay CC, et al. Aromatase inhibitors are associated with a higher fracture risk than tamoxifen: a systematic review and meta-analysis. Ther Adv Musculoskelet Dis. 2018;10:71–90.
Bouchard C. Selective estrogen receptor modulators and their effects on hot flashes: a dilemma. Menopause. 2011;18:477–479.
Fleming CA, Heneghan HM, O’Brien D, et al. Meta-analysis of the cumulative risk of endometrial malignancy and systematic review of endometrial surveillance in extended tamoxifen therapy. Br J Surg. 2018;105:1098–1106.
Committee Opinion No. 601: Tamoxifen and uterine cancer. Obstet Gynecol. 2014.
Stovall DW, Utian W, Gass M, et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause. 2007;14:510–517.
Neven P, Quail D, Marin F, et al. Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: review of Euralox 1. Maturitas. 2005;52:87–101.
Cranney A, Tugwell P, Zytaruk N, et al. Osteoporosis meta-analyses of therapies for postmenopausal osteoporosis. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev. 2002;23:524–528.
Pinkerton JV, Utian WH, Constantine GD, et al. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause. 2009;16:1116–1124.
Harvey JA, Pinkerton JV, Baracat EC, et al. Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens. Menopause. 2013;20:138–145.
Pinkerton JV, Harvey JA, Pan K, et al. Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. Obstet Gynecol. 2013;121:959–968.
Pinkerton JV, Harvey JA, Lindsay R, et al. SMART-5 Investigators. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab. 2014;99:E189–E198.
Di Donato V, Schiavi MC, Iacobelli V, et al. Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part I: evaluation of efficacy. Maturitas. 2019;121:86–92.
Di Donato V, Schiavi MC, Iacobelli V, et al. Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials. Part II: evaluation of tolerability and safety. Maturitas. 2019;121:93–100.
Constantine G, Graham S, Portman DJ, et al. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric. 2015;18:226–232.
Constantine G, Archer DF, Pollycove R, et al. Effects of ospemifene on vasomotor symptoms in phase 2 and 3 clinical trials. Menopause. 2016;23:957–964.
Lainé M, Fanning SW, Chang YF, et al. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res. 2021;23:54.
Gérard C, Mestdagt M, Tskitishvili E, et al. Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms. Oncotarget. 2015;6:17621–17636.
Klipping C, Duijkers I, Mawet M, et al. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone. Contraception. 2021;103:213–222.
Gaspard U, Taziaux M, Mawet M, et al. A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part I. Vasomotor symptoms and overall safety. Menopause. 2020;27:848–857.
Peng L, Luo Q, Lu H. Efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: a systematic review and meta-analysis. Medicine (Baltimore). 2017;96:e8659.